Medical - Devices
Compare Stocks
5 / 10Stock Comparison
STE vs MMSI vs HSIC vs NVCR vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Distribution
Medical - Instruments & Supplies
Medical - Instruments & Supplies
STE vs MMSI vs HSIC vs NVCR vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Distribution | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $21.00B | $3.72B | $8.09B | $1.92B | $16.97B |
| Revenue (TTM) | $5.83B | $1.54B | $13.18B | $674M | $4.13B |
| Net Income (TTM) | $708M | $139M | $398M | $-173M | $544M |
| Gross Margin | 44.1% | 48.7% | 29.1% | 75.2% | 52.8% |
| Operating Margin | 17.2% | 12.2% | 5.8% | -27.2% | 17.5% |
| Forward P/E | 21.0x | 15.5x | 13.3x | — | 17.2x |
| Total Debt | $2.20B | $898M | $3.69B | $290M | $2.63B |
| Cash & Equiv. | $172M | $449M | $156M | $103M | $1.96B |
STE vs MMSI vs HSIC vs NVCR vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| STERIS plc (STE) | 100 | 128.8 | +28.8% |
| Merit Medical Syste… (MMSI) | 100 | 138.5 | +38.5% |
| Henry Schein, Inc. (HSIC) | 100 | 116.1 | +16.1% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: STE vs MMSI vs HSIC vs NVCR vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
STE is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 14 yrs, beta 0.69, yield 1.0%
- 220.0% 10Y total return vs HOLX's 124.3%
- PEG 3.86 vs HSIC's 4.21
- 1.0% yield; 14-year raise streak; the other 4 pay no meaningful dividend
MMSI ranks third and is worth considering specifically for growth exposure.
- Rev growth 11.7%, EPS growth 4.9%, 3Y rev CAGR 9.6%
- 11.7% revenue growth vs HOLX's 1.7%
HSIC is the clearest fit if your priority is value.
- Lower P/E (13.3x vs 17.2x)
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
HOLX carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
- 13.2% margin vs NVCR's -25.7%
- Beta 0.41 vs NVCR's 2.20, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.7% revenue growth vs HOLX's 1.7% | |
| Value | Lower P/E (13.3x vs 17.2x) | |
| Quality / Margins | 13.2% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.41 vs NVCR's 2.20, lower leverage | |
| Dividends | 1.0% yield; 14-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +37.1% vs MMSI's -33.8% | |
| Efficiency (ROA) | 6.7% ROA vs NVCR's -16.5%, ROIC 7.2% vs -16.4% |
STE vs MMSI vs HSIC vs NVCR vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
STE vs MMSI vs HSIC vs NVCR vs HOLX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
STE leads in 3 of 6 categories
HOLX leads 2 • HSIC leads 1 • MMSI leads 0 • NVCR leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
HOLX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HSIC is the larger business by revenue, generating $13.2B annually — 19.5x NVCR's $674M. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5.8B | $1.5B | $13.2B | $674M | $4.1B |
| EBITDAEarnings before interest/tax | $1.4B | $290M | $1.1B | -$165M | $974M |
| Net IncomeAfter-tax profit | $708M | $139M | $398M | -$173M | $544M |
| Free Cash FlowCash after capex | $917M | $274M | $561M | -$48M | $1000M |
| Gross MarginGross profit ÷ Revenue | +44.1% | +48.7% | +29.1% | +75.2% | +52.8% |
| Operating MarginEBIT ÷ Revenue | +17.2% | +12.2% | +5.8% | -27.2% | +17.5% |
| Net MarginNet income ÷ Revenue | +12.1% | +9.0% | +3.0% | -25.7% | +13.2% |
| FCF MarginFCF ÷ Revenue | +15.7% | +17.8% | +4.3% | -7.1% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.2% | +7.8% | +7.7% | +12.3% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.0% | +38.8% | +14.9% | -100.0% | -9.2% |
Valuation Metrics
HSIC leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 37% valuation discount to STE's 34.5x P/E. Adjusting for growth (PEG ratio), STE offers better value at 6.35x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $21.0B | $3.7B | $8.1B | $1.9B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $23.0B | $4.2B | $11.6B | $2.1B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | 34.46x | 29.26x | 21.56x | -13.80x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.95x | 15.46x | 13.26x | — | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | 6.35x | — | 6.84x | — | — |
| EV / EBITDAEnterprise value multiple | 17.15x | 13.06x | 10.87x | — | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 3.85x | 2.45x | 0.61x | 2.92x | 4.14x |
| Price / BookPrice ÷ Book value/share | 3.20x | 2.38x | 1.79x | 5.51x | 3.43x |
| Price / FCFMarket cap ÷ FCF | 27.00x | 17.24x | 14.12x | — | 18.44x |
Profitability & Efficiency
STE leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-51 for NVCR. STE carries lower financial leverage with a 0.33x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), STE scores 8/9 vs HSIC's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.9% | +8.9% | +8.2% | -50.8% | +11.0% |
| ROA (TTM)Return on assets | +6.7% | +5.2% | +3.6% | -16.5% | +6.1% |
| ROICReturn on invested capital | +7.2% | +7.2% | +7.1% | -16.4% | +9.4% |
| ROCEReturn on capital employed | +9.0% | +7.9% | +9.8% | -28.9% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 6 | 4 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.33x | 0.57x | 0.77x | 0.85x | 0.52x |
| Net DebtTotal debt minus cash | $2.0B | $450M | $3.5B | $187M | $667M |
| Cash & Equiv.Liquid assets | $172M | $449M | $156M | $103M | $2.0B |
| Total DebtShort + long-term debt | $2.2B | $898M | $3.7B | $290M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | 15.94x | 10.74x | 4.59x | -96.80x | 8.00x |
Total Returns (Dividends Reinvested)
STE leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HOLX five years ago would be worth $11,582 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HOLX leads with a +37.1% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors STE at 5.3% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -14.3% | -27.9% | -8.2% | +28.3% | +1.9% |
| 1-Year ReturnPast 12 months | -3.9% | -33.8% | +5.9% | +1.1% | +37.1% |
| 3-Year ReturnCumulative with dividends | +16.6% | -26.5% | -11.7% | -75.7% | -8.5% |
| 5-Year ReturnCumulative with dividends | +5.9% | -3.6% | -12.5% | -91.3% | +15.8% |
| 10-Year ReturnCumulative with dividends | +220.0% | +214.6% | +5.3% | +30.3% | +124.3% |
| CAGR (3Y)Annualised 3-year return | +5.3% | -9.8% | -4.0% | -37.6% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.69x | 0.71x | 0.73x | 2.20x | 0.41x |
| 52-Week HighHighest price in past year | $269.44 | $100.19 | $89.29 | $20.06 | $76.04 |
| 52-Week LowLowest price in past year | $204.81 | $59.74 | $61.95 | $9.82 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +79.3% | +62.2% | +79.0% | +83.9% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 34.9 | 39.1 | 69.8 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 710K | 769K | 1.2M | 1.5M | 10.0M |
Analyst Outlook
STE leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: STE as "Buy", MMSI as "Buy", HSIC as "Hold", NVCR as "Buy", HOLX as "Hold". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 3.9% for HOLX (target: $79). STE is the only dividend payer here at 1.04% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | $256.67 | $95.00 | $86.43 | $33.50 | $79.00 |
| # AnalystsCovering analysts | 13 | 13 | 32 | 15 | 42 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 14 | — | 1 | — | — |
| Dividend / ShareAnnual DPS | $2.22 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.0% | 0.0% | +10.5% | 0.0% | +4.4% |
STE leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). HOLX leads in 2 (Income & Cash Flow, Risk & Volatility).
STE vs MMSI vs HSIC vs NVCR vs HOLX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is STE or MMSI or HSIC or NVCR or HOLX a better buy right now?
For growth investors, Merit Medical Systems, Inc.
(MMSI) is the stronger pick with 11. 7% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate STERIS plc (STE) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — STE or MMSI or HSIC or NVCR or HOLX?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus STERIS plc at 34. 5x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: STERIS plc wins at 3. 86x versus Henry Schein, Inc. 's 4. 21x.
03Which is the better long-term investment — STE or MMSI or HSIC or NVCR or HOLX?
Over the past 5 years, Hologic, Inc.
(HOLX) delivered a total return of +15. 8%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: STE returned +220. 0% versus HSIC's +5. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — STE or MMSI or HSIC or NVCR or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, STERIS plc (STE) carries a lower debt/equity ratio of 33% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — STE or MMSI or HSIC or NVCR or HOLX?
By revenue growth (latest reported year), Merit Medical Systems, Inc.
(MMSI) is pulling ahead at 11. 7% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: STERIS plc grew EPS 62. 7% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, MMSI leads at 9. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — STE or MMSI or HSIC or NVCR or HOLX?
Hologic, Inc.
(HOLX) is the more profitable company, earning 13. 8% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is STE or MMSI or HSIC or NVCR or HOLX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, STERIS plc (STE) is the more undervalued stock at a PEG of 3. 86x versus Henry Schein, Inc. 's 4. 21x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 3x forward P/E versus 21. 0x for STERIS plc — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — STE or MMSI or HSIC or NVCR or HOLX?
In this comparison, STE (1.
0% yield) pays a dividend. MMSI, HSIC, NVCR, HOLX do not pay a meaningful dividend and should not be held primarily for income.
09Is STE or MMSI or HSIC or NVCR or HOLX better for a retirement portfolio?
For long-horizon retirement investors, STERIS plc (STE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
69), 1. 0% yield, +220. 0% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STE: +220. 0%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between STE and MMSI and HSIC and NVCR and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
STE pays a dividend while MMSI, HSIC, NVCR, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.